Meydson Benjamim Carvalho Corrêa

Meydson Benjamim Carvalho Corrêa

Auto-generated profile, based on publicly available information

Meydson Benjamim Carvalho Corrêa

Laboratório de Hanseníase, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in Microbes and Infection
Verified
Journal Article
Closed access
SRSabrina Alves dos Reis
Sabrina Alves dos Reis
JGJessica Dias Gonçalves
Jessica Dias Gonçalves
KLKaroline dos Anjos Lima
Karoline dos Anjos Lima
TDThaina Magalhaes Demaria
Thaina Magalhaes Demaria
ECEmylle Costa-Bartuli
Emylle Costa-Bartuli
FLFlavio Alves Lara
Flavio Alves Lara

27 October 2023 in AMB Express
Verified
Journal Article
Open access
PDF file
MLMayara Lima
Mayara Lima
MCMeydson Benjamim Carvalho Corrêa
Meydson Benjamim Carvalho Corrêa
EMEmilly Caroline dos Santos Moraes
Emilly Caroline dos Santos Moraes
JOJaqueline das Dores Dias Oliveira
Jaqueline das Dores Dias Oliveira
PSPaula de Souza Santos
Paula de Souza Santos
LGLuiz Ricardo Goulart
Luiz Ricardo Goulart
The early diagnosis of leprosy serves as an important tool to reduce the incidence of this disease in the world. Phage display (PD) technology can be used for mapping new antigens to the development of immunodiagnostic platforms. Our objective was to identify peptides that mimic Mycobacterium leprae proteins as serological markers using phage display technology. The phages were obtained in the biopanning using negative and positive serum from household contacts and leprosy patients, respectively. Then, the peptides were synthesized and validated in silico and in vitro for detection of IgG from patients and contacts. To characterize the native protein of M. leprae, scFv antibodies were selected against the synthetic peptides by PD. The scFv binding protein was obtained by immunocapture and confirmed using mass spectrometry. We selected two phase-fused peptides, MPML12 and MPML14, which mimic the HSP60 protein from M. leprae. The peptides MPML12 and MPML14 obtained 100% and 92.85% positivity in lepromatous patients. MPML12 and MPM14 detect IgG, especially in the multibacillary forms. The MPML12 and MPML14 peptides had positivity of 11.1% and 16.6% in household contacts, respectively. There was no cross-reaction in patient’s samples with visceral leishmaniasis, tuberculosis and other mycobacteriosis for both peptides. Given these results and the easy obtainment of mimetic antigens, our peptides are promising markers for application in the diagnosis of leprosy, especially in endemic and hyperendemic regions.